FRA
RLMD icon

Front Row Advisors’s Relmada Therapeutics RLMD Stock Holding History

Front Row Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$10 – 567
2025
Q4 		$10 Hold
2
– – ﹤0.01% 549
2025
Q3 		$4 Sell
2
-1
-33% -$1 ﹤0.01% 551
2025
Q2 		$2 Sell
3
-3
-50% -$2 ﹤0.01% 538
2025
Q1 		$2 Buy
+6
New +$2 ﹤0.01% 511
2024
Q4 		– Sell
-6
Closed -$19 – 506
2024
Q3 		$19 Hold
6
– – ﹤0.01% 499
2024
Q2 		$18 Hold
6
– – ﹤0.01% 937
2024
Q1 		$28 Hold
6
– – ﹤0.01% 923
2023
Q4 		$25 Hold
6
– – ﹤0.01% 469
2023
Q3 		$18 Hold
6
– – ﹤0.01% 916
2023
Q2 		$0 Hold
6
– – ﹤0.01% 942
2023
Q1 		$0 Buy
+6
New +$21 ﹤0.01% 946

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Front Row Advisors's RLMD Position: Q1 2026 in Review

Front Row Advisors sold out of Relmada Therapeutics (RLMD) in Q1 2026, closing a stake of 2 shares — an estimated $10 sold.

Front Row Advisors first reported a position in RLMD in Q1 2023 and held it in 11 quarters. The position peaked at $28 in Q1 2024. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Front Row Advisors reported no remaining Relmada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Front Row Advisors sold 2 Relmada Therapeutics shares in Q1 2026, an estimated $10.
  • Front Row Advisors first reported a position in Relmada Therapeutics in Q1 2023 and held it in 11 quarters.
  • Front Row Advisors's Relmada Therapeutics position peaked at $28 in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.